Shanmuga Hospital Limited reported a net profit of ₹98.65 lakh for the quarter ended June 30, 2026, driven by a 3.4% year-on-year rise in revenue to ₹1,186.71 lakh. The company’s earnings per share (EPS) stood at ₹0.72, compared to ₹0.70 in the same quarter last year. Alongside the financial results, the Board approved a new Employee Stock Option Plan (ESOP) and proposed an increase in authorized share capital, signaling strategic steps for future growth and employee retention.

The Board meeting held on August 11, 2026, reviewed and approved the unaudited standalone financial results as recommended by the Audit Committee. The results were subjected to a limited review by P P N And Company, the statutory auditors, in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company voluntarily disclosed these quarterly figures to enhance investor transparency, although such disclosures are not mandatory under the SME Listing framework.

Financial Performance

Revenue from operations increased to ₹1,186.71 lakh in Q1FY27 from ₹1,148.21 lakh in Q1FY26. Total income for the quarter was ₹1,190.98 lakh, inclusive of other income of ₹4.27 lakh. Operating expenses remained controlled, with cost of consumption declining significantly to ₹268.72 lakh from ₹381.41 lakh in the prior year period. However, employee benefits expenses rose to ₹221.68 lakh from ₹140.63 lakh, reflecting potential investments in human resources or salary revisions.

Profit before tax rose marginally by 1.3% to ₹131.56 lakh. Tax expense for the quarter was ₹32.91 lakh, comprising current tax of ₹22.90 lakh and deferred tax of ₹10.01 lakh.

Strategic Approvals and Corporate Actions

The Board approved the formulation of the "Shanmuga Hospital Limited Employee Stock Option Plan 2026" (SHL ESOP-2026). Under this plan, the company can grant up to 3,50,000 equity shares, representing 2.58% of the total paid-up equity share capital. The exercise price will be determined by the Nomination and Remuneration Committee (NRC) and will not be less than the face value or more than the closing market price on the day preceding the grant. Options will vest between one and three years from the date of grant.

Additionally, the Board approved an increase in the authorized share capital from ₹14 crore (1,40,00,000 equity shares) to ₹25 crore (2,50,00,000 equity shares). This proposal, along with alterations to the Main Object Clause of the Memorandum of Association (MOA) and amendments to the Articles of Association (AOA), requires shareholder approval at the upcoming Annual General Meeting (AGM).

What the Numbers Show

The divergence between revenue growth and expense management highlights a shift in operational focus. While revenue grew by 3.4%, the cost of consumption dropped sharply by nearly 30% year-on-year, suggesting improved procurement efficiency or changes in service mix. Conversely, the significant jump in employee benefits expenses (57.6% increase) indicates that the company is likely investing heavily in talent acquisition or retention, which aligns with the simultaneous approval of a new ESOP scheme. This suggests a long-term strategy to stabilize and grow its workforce despite near-term pressure on operating margins.

Upcoming AGM Details

The 6th Annual General Meeting is scheduled for September 18, 2026, at 2:30 P.M., to be conducted via Video Conferencing or Other Audio-Visual Means. The record date for determining eligibility to receive notices and vote is September 11, 2026. The register of members and share transfer books will remain closed from September 12, 2026, to September 18, 2026. CS Santhanakrishna Anuradha has been appointed as the scrutinizer for the AGM.

Shanmuga Hospital Ltd has initiated a pilot public testing phase of its mobile application, Shanmuga 360, to validate operational performance and gather user feedback. The digital healthcare application is intended to provide patients with convenient access to various healthcare services through a single platform. This move aims to ensure operational stability, user experience, security, and service efficiency before a full-scale rollout.

The application has been made available on the Google Play Store and Apple App Store for the limited purpose of operational testing. During this pilot phase, certain features and services have been enabled in a controlled manner, and access may be restricted to specified testing periods. The company stated that the present availability of the application does not constitute its official commercial launch.

Testing and Validation

The pilot rollout is focused on performance validation and the collection of user feedback. The company has emphasized that the application is still undergoing testing to ensure all intended features and services are fully operational. The official commercial launch will be undertaken only upon the successful completion of this testing process.

Future Announcements

Shanmuga Hospital Ltd will make a separate announcement to the Stock Exchange regarding the official commercial launch at the appropriate time. This disclosure was made in the interest of transparency, as the application has been made available in the public domain for pilot testing purposes.